ドラベ症候群（DS）市場：1次調査（競合情報、市場分析と予測 - 2032年）
Dravet Syndrome (DS) | Primary Research (KOL's Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
|ドラベ症候群（DS）市場：1次調査（競合情報、市場分析と予測 - 2032年）|
発行: Mellalta Meets LLP
ページ情報: 英文 141 Pages
Growth of the incidence DS population will contribute to increasing sales in the DS therapy market over our forecast period. An estimated annual growth rate of ~1% in the diagnosed incident DS population across the major pharmaceutical markets will contribute to increasing DS therapy sales. In 2018, the drug-treated cases of Dravet Syndrome (DS) in Brazil & Mexico were 8,392 cases. These cases are expected to increase to 11,335 cases in 2032 owing to changes in population demographics and increasing cases of DS.
The continuous involvement of supportive treatments including antiepileptic therapies for the management of DS patients will contribute to the overall growth of the DS therapy market. We forecast that total sales of the total care market will reach $276 Million by 2032.
Dravet syndrome is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems. DS is considered an epileptic encephalopathy due to seizures. In addition, it is considered a "channelopathy" because the effects of the mutation on the sodium channel appear to contribute to the disorder independently of the seizures.
We estimate the total number of Dravet Syndrome (DS) prevalent cases in the Brazil and Mexico of 1:20,000 or 0.005%. There is a significant amount of shortage of large-scale epidemiological reports. The rarity of the disease further compounds the problem at hand as there exists a lack of firmly established and specific diagnostic criteria and some of the studies may have chances of biasness depending on the geographical area studied. There also exists methodological challenges for researchers due to measurements involving a small sample population.
According to the KOLs View, approximately 50% of the cases of Dravet Syndrome (DS) are diagnosed. Patients with Dravet syndrome may be misdiagnosed with myoclonic atonic epilepsy, Lennox-Gastaut syndrome, myoclonic epilepsy of infancy, genetic epilepsy with febrile seizures plus, atypical febrile seizures, and mitochondrial disorders. Additionally, some children may be diagnosed with focal epilepsy.
The Dravet Syndrome (DS) therapy market is expected to experience high growth throughout our study period, increasing from $XX billion in 2018 to $XX billion in 2032, representing ~1% annual growth. Primary drivers of this growth will be uptake of the novel upcoming treatment like Soticlestat (Takeda/Ovid Therapeutics), Lorcaserin (Eisai/Arena Pharmaceuticals), STK 001 (Stoke Therapeutics, Inc), EPX 100 (Epygenix Therapeutics), ETX101 (Encoded Therapeutics).
Most interviewed experts believe that patients will benefit from the upcoming therapies based on targeting CH24H inhibitors, selective serotonin 5-HT2c receptor, NAV1.1 Voltage-gated Sodium Channel Modulators and Specific GABAA Receptor have the potential to increase the therapeutic options for Dravet Syndrome (DS) patients. Expected launch of late-stage product such as Soticlestat, Lorcaserin and STK 001 are likely to change the current treatment paradigm for Dravet Syndrome (DS) and these approved therapies will be more preferrable in the future.